Winkler René, Kosan Christian
Department of Biochemistry, Center for Molecular Biomedicine (CMB), Friedrich-Schiller-University Jena, Hans-Knöll-Str. 2, 07745, Jena, Germany.
Methods Mol Biol. 2017;1510:93-101. doi: 10.1007/978-1-4939-6527-4_7.
Histone deacetylase inhibitors (HDACi) are used as therapeutics for several B cell-derived malignancies. Furthermore, they have been shown to modulate the response of the immune system, like the B cell function. HDACi treatment affects differentiation, proliferation, and survival of B cells. Here we describe how to investigate the effects of HDACi treatment on naïve B cells regarding class-switch recombination (CSR) in vitro using flow cytometry.
组蛋白去乙酰化酶抑制剂（HDACi）被用作多种B细胞源性恶性肿瘤的治疗药物。此外，它们已被证明可调节免疫系统的反应，如B细胞功能。HDACi治疗会影响B细胞的分化、增殖和存活。在这里，我们描述了如何使用流式细胞术在体外研究HDACi治疗对初始B细胞类别转换重组（CSR）的影响。
